Confronto

Glepaglutide vs. Lanreotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

108736-35-2

Peso molecolare

nessun dato

1096.34 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Lanreotid
Germania	Non approvato	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Lanreotid?: Glepaglutide is classified as "Ricerca (altro)", while Lanreotid is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Lanreotid?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Lanreotid in Germany and the United States?: Germania: Glepaglutide — Non approvato, Lanreotid — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Lanreotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Lanreotid

Germania

Non approvato

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Glepaglutide and Lanreotid?

Glepaglutide is classified as "Ricerca (altro)", while Lanreotid is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Lanreotid?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Lanreotid in Germany and the United States?

Germania: Glepaglutide — Non approvato, Lanreotid — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Lanreotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.